1,3-dihydro-2-phenalenone | 39054-97-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 非那烯类
• 英文名称: 1,3-dihydro-2-phenalenone
• 英文别名: 1,3-dihydrophenalen-2-one
• CAS: 39054-97-2
• 化学式: C₁₃H₁₀O
• 分子量: 182.222
• InChiKey: NAELYKSAHIYOSK-UHFFFAOYSA-N

物化性质

• 沸点：
  379.1±31.0 °C(Predicted)
• 密度：
  1?+-.0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1,3-dihydro-2-phenalenone 生成 13-chloro-12-oxa-13λ4-tellura-11-azatetracyclo[7.6.1.05,16.010,14]hexadeca-1,3,5(16),6,8,10,13-heptaene
  参考文献：
  名称：

  PRZYKLEK-ELLING, ROSEMARY;GUNTHER, WOLFGANG H. H.;LOK, ROGER

  摘要：

  DOI：
• 作为产物：
  描述：

  1,8-双(溴甲基)萘 在 盐酸 、 sodium 、 肼 、 sodium nitrite 作用下， 以 乙醇 、 氯仿 、 水 、 溶剂黄146 、 苯 为溶剂， 反应 23.0h， 生成 1,3-dihydro-2-phenalenone
  参考文献：
  名称：

  Joergensen, Flemming S.; Thomsen, Tove, Acta chemica Scandinavica. Series B: Organic chemistry and biochemistry, 1984, vol. 38, # 2, p. 113 - 116

  摘要：

  DOI：

文献信息

• Method for the in situ preparation of chiral compounds derived from oxazaborolidine-borane complexes which are used in asymmetric reduction reactions
  申请人：Burgos Alain

  公开号：US20070055068A1

  公开（公告）日：2007-03-08

  A process for the in situ preparation of chiral compounds derived from oxazaborolidine-borane complexes, wherein a metal borohydride, a Lewis base and an inorganic acid ester are brought together and an optically active amino alcohol and optionally a halide are then added. The compound obtained is a complex that is useful as a catalyst in asymmetric reduction reactions. The reaction is performed by adding the substance to be reduced, particularly prochiral ketones or ether oximes, in order to synthesize chiral alcohols or chiral amines.

  一种用于原位制备从氧杂硼烷硼酸盐复合物中衍生的手性化合物的方法，其中将金属硼氢化物、路易斯碱和无机酸酯混合，然后加入手性活性氨基醇和可选的卤化物。所得化合物是一种复合物，可用作不对称还原反应中的催化剂。通过将待还原物质，特别是原始手性酮或醚肟加入以合成手性醇或手性胺来执行反应。
• Benzospiroalkene heterocyclic compounds
  申请人：Adir et Compagnie

  公开号：US05436261A1

  公开（公告）日：1995-07-25

  Compounds of formula (I): ##STR1## in which: X represents --CH.sub.2 --, --(CH.sub.2).sub.2 --, --CH.dbd.CH--, --O--CH.sub.2 --, --S--CH.sub.2 --, --SO--CH.sub.2 -- or --SO.sub.2 --CH.sub.2 --, Y represents oxygen or sulfur or --NR.sub.6 --, R.sub.1 represents hydrogen or linear or branched (C.sub.1 -C.sub.6) alkyl, R.sub.2 represents hydrogen or halogen, linear or branched (C.sub.1 -C.sub.6) alkyl, (substituted or unsubstituted), hydroxyl, linear or branched (C.sub.1 -C.sub.6) alkoxy or linear or branched (C.sub.1 -C.sub.6) alkylthio, R.sub.3 represents hydrogen or halogen, linear or branched (C.sub.1 -C.sub.6) alkyl (substituted or unsubstituted), hydroxyl, linear or branched (C.sub.1 -C.sub.6) alkoxy or linear or branched (C.sub.1 -C.sub.6)alkylthio, R.sub.4 represents hydrogen (on condition that, in this case, R.sub.1 represents hydrogen), halogen, linear or branched (C.sub.1 -C.sub.6) alkyl (substituted or unsubstituted) or hydroxyl, or alternatively R.sub.1 and R.sub.2, R.sub.2 and R.sub.3, R.sub.3 and R.sub.4 or R.sub.4 and X, together with the carbon atoms which bear them, form a benzene ring, on condition that, in the case where R.sub.1 and R.sub.2 form a benzene ring, X is other than --CH.sub.2 -- or --(CH.sub.2).sub.2 --, R.sub.5 represents hydrogen or amino (substituted or unsubstituted), R.sub.6 has the same meaning as R.sub.1, their isomers and also their. addition salts with a pharmaceutically acceptable acid and medicinal product containing the sarne are useful as partial .alpha..sub.1 and .alpha..sub.2 adrenergic agonist in the treatment of venous disease and migraine.

  式(I)的化合物：##STR1## 其中：X代表--CH.sub.2 --，--(CH.sub.2).sub.2 --，--CH.dbd.CH--，--O--CH.sub.2 --，--S--CH.sub.2 --，--SO--CH.sub.2 --或--SO.sub.2 --CH.sub.2 --，Y代表氧或硫或--NR.sub.6 --，R.sub.1代表氢或线性或支链（C.sub.1-C.sub.6）烷基，R.sub.2代表氢或卤素，线性或支链（C.sub.1-C.sub.6）烷基，（取代或未取代）羟基，线性或支链（C.sub.1-C.sub.6）烷氧基或线性或支链（C.sub.1-C.sub.6）烷基硫基，R.sub.3代表氢或卤素，线性或支链（C.sub.1-C.sub.6）烷基（取代或未取代），羟基，线性或支链（C.sub.1-C.sub.6）烷氧基或线性或支链（C.sub.1-C.sub.6）烷基硫基，R.sub.4代表氢（在这种情况下，R.sub.1代表氢），卤素，线性或支链（C.sub.1-C.sub.6）烷基（取代或未取代）或羟基，或者R.sub.1和R.sub.2，R.sub.2和R.sub.3，R.sub.3和R.sub.4或R.sub.4和X，连同它们所带的碳原子，形成苯环，在R.sub.1和R.sub.2形成苯环的情况下，X不同于--CH.sub.2 --或--(CH.sub.2).sub.2 --，R.sub.5代表氢或氨基（取代或未取代），R.sub.6与R.sub.1具有相同的含义，它们的异构体以及与药学上可接受的酸的加合物和含有相同的药物产品在静脉疾病和偏头痛治疗中作为部分.alpha..sub.1和.alpha..sub.2肾上腺素受体激动剂是有用的。
• Aromatic stacking in folded architectures through hydrogen bonding
  作者：Yaun-Shek Chen、Jeff W Kampf、Richard G Lawton

  DOI：10.1016/s0040-4039(97)01318-x

  日期：1997.8

  The alpha, alpha'-annelation of the enamine of 1,3-hydro-2-phenalenone with methyl alpha-(bromomethyl)acrylate affords an aromatic bicyclic framework, methyl 8,9,10,11-tetrahydro-7,11-methano-12-keto-7H-cyclooocta(de)naphthalene-9-endo-carboxylate having the ester function positioned over the aromatic ring. The acid derivatives of this framework dimerize affording a ''sandwich'' structure with the H-bonded carboxyl groups between parallel naphthalene rings. The dimeric association can be easily probed using both NMR and fluorescence techniques. (C) 1997 Elsevier Science Ltd.
• JORGENSEN, F. S.;THOMSEN, T., ACTA CHEM. SCAND., 1984, 38, N 2, 113-116
  作者：JORGENSEN, F. S.、THOMSEN, T.

  DOI：——

  日期：——
• PRZYKLEK-ELLING, ROSEMARY;GUNTHER, WOLFGANG H. H.;LOK, ROGER
  作者：PRZYKLEK-ELLING, ROSEMARY、GUNTHER, WOLFGANG H. H.、LOK, ROGER

  DOI：——

  日期：——